7 research outputs found
Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse outcomes after a cardiovascular event has occurred. This situation might be caused, at least in part, by the prothrombotic status observed in patients with diabetes. Therefore, contemporary antithrombotic strategies, including more potent agents or drug combinations, might provide greater clinical benefit in patients with diabetes than in those without diabetes. In this Consensus Statement, our Working Group explores the mechanisms of platelet and coagulation activity, the current debate on antiplatelet therapy in primary cardiovascular disease prevention, and the benefit of various antithrombotic approaches in secondary prevention of cardiovascular disease in patients with diabetes. While acknowledging that current data are often derived from underpowered, observational studies or subgroup analyses of larger trials, we propose antithrombotic strategies for patients with diabetes in various cardiovascular settings (primary prevention, stable coronary artery disease, acute coronary syndromes, ischaemic stroke and transient ischaemic attack, peripheral artery disease, atrial fibrillation, and venous thromboembolism). Finally, we summarize the improvements in cardiovascular outcomes observed with the latest glucose-lowering drugs, and on the basis of the available evidence, we expand and integrate current guideline recommendations on antithrombotic strategies in patients with diabetes for both primary and secondary prevention of cardiovascular disease
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper.
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper
Although the female gender is generally less represented in cardiovascular studies, observational and randomized investigations suggest that-compared with men-women may obtain different benefits from antiplatelet therapy. Multiple factors, including hormonal mechanisms and differences in platelet biology, might contribute to such apparent gender peculiarities. The thrombotic and bleeding risks, as well as outcomes after a cardiovascular event, appear to differ between genders, partly in relation to differences in age, comorbidities and body size. Equally, the benefits of antiplatelet therapy may differ in women compared with men in different vascular beds, during primary or secondary prevention and according to the type of an antiplatelet agent used. This document is an attempt to bring together current evidence, clinical practices and gaps of knowledge on gender-specific platelet function and antiplatelet therapy. On the basis of the available data, we provide suggestions on current indications of antiplatelet therapy for cardiovascular prevention in women with different clinical features; no strong recommendation may be given because the available data derive from observational studies or post hoc/subgroup analyses of randomized studies without systematic adjustments for baseline risk profiles. Published on behalf of the European Society of Cardiology. All rights reserved
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper
Although the female gender is generally less represented in cardiovascular studies, observational and randomized investigations suggest that\u2014
compared with men\u2014women may obtain different benefits from antiplatelet therapy. Multiple factors, including hormonal mechanisms and differences
in platelet biology, might contribute to such apparent gender peculiarities. The thrombotic and bleeding risks, aswell as outcomes after a
cardiovascular event, appear to differ between genders, partly in relation to differences in age, comorbidities and body size. Equally, the benefits of
antiplatelet therapy may differ in women compared with men in different vascular beds, during primary or secondary prevention and according to
the type of an antiplatelet agent used. This document is an attempt to bring together current evidence, clinical practices and gaps of knowledge on
gender-specific platelet function and antiplatelet therapy.Onthe basis of the available data,we provide suggestions on current indications of antiplatelet
therapy for cardiovascular prevention in women with different clinical features; no strong recommendation may be given because the
available data derive fromobservational studies or post hoc/subgroup analyses of randomized studies without systematic adjustments for baseline risk profiles